Advent Life Sciences
Advent Life Sciences is a London-based venture capital firm (LLP) founded in 2006 that invests Seed through Series C in early and mid-stage life sciences companies across the UK, Europe, and the USA, backing first-in-class or best-in-class drug discovery, med tech, enabling technologies, and vaccines.
- Company typePrivate
- Founded2006
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Advent Life Sciences does
Advent Life Sciences LLP is a London-based venture capital firm, structured as an LLP, that has been investing in life sciences companies since 2006 across the UK, Europe, and the United States. The firm focuses on early and mid-stage businesses with first-in-class or best-in-class approaches spanning new drug discovery across all modalities, med tech, enabling technologies, and vaccines. It typically invests at Seed through Series C stages and frequently takes lead or co-lead positions, working in close operational partnership with portfolio management teams.
The firm's single core service is venture investment in life sciences; its "product" is capital plus intellectual and network support rather than a technology platform. Reported portfolio activity since 2020 includes lead investments in Amphista Therapeutics ($7.5M Series A, targeted protein degradation) and PIC Therapeutics ($5M Seed, eIF4E modulators), and participation in rounds for Beacon Therapeutics ($75M+ Series C, ocular gene therapy), Cyted Health ($44M Series B, GI diagnostics), Glycomine ($115M Series C, PMM2-CDG), Relief Cardiovascular ($12M Series A), Epitopea ($31M pre-Series A), and Pheno Therapeutics (£5M Series A, MS remyelination). Portfolio milestones include the October 2024 FDA approval of Iterum Therapeutics' ORLYNVAH (the first oral penem approved in the US) and the October 2025 US approval of Bayer's Lynkuet (elinzanetant), originally developed by Advent-backed KaNDy Therapeutics.
Advent generates revenue through traditional VC mechanics: management fees on committed fund capital and realized investment gains from portfolio exits via acquisitions, IPOs (e.g., Aura Biosciences, NASDAQ: AURA), or strategic transactions. The firm claims that since 2006, Advent-backed companies have brought 15 innovative medicines and products to approval, with the mid- and late-stage clinical pipeline expected to drive additional exits. The firm is privately held, has 11-50 employees, and its financial figures are not publicly disclosed.
Advent Life Sciences firmographics
Firmographics- Name
- Advent Life Sciences
- Legal name
- Advent Life Sciences LLP
- Website
- https://adventls.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Advent Life Sciences is a London-based venture capital firm (LLP) founded in 2006 that invests Seed through Series C in early and mid-stage life sciences companies across the UK, Europe, and the USA, backing first-in-class or best-in-class drug discovery, med tech, enabling technologies, and vaccines.
- Ownership category
- akta.pro rank
Advent Life Sciences industry classification
Industry- Product category
- Venture Capital (Life Sciences)
- NAICS
- Other Scientific and Technical Consulting Services (54169), Scientific Research and Development Services (5417)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
Keywords
Where Advent Life Sciences is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Advent Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D
Revenue model
- Investment Returns: Advent Life Sciences generates returns through equity investments in portfolio companies, realizing gains through exits via acquisitions, IPOs, or other strategic transactions. Since 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Advent Life Sciences product offering
Product offeringCore offering
Advent Life Sciences is a trans-Atlantic venture capital firm that founds and invests in early and mid-stage life sciences companies with first-in-class or best-in-class approaches to unmet medical needs. The firm provides venture capital, strategic guidance, and operational support across new drug discovery (all modalities), med tech, enabling technologies, and vaccines. It takes a hands-on, partnership-oriented approach working closely with portfolio management teams to advance breakthrough science toward approved medicines and medical products.
Product overview
Advent Life Sciences is a venture capital firm offering a single unified investment service rather than a product portfolio. The firm focuses on identifying, funding, and supporting early and mid-stage life sciences companies developing innovative medicines and medical technologies. Their investment approach emphasizes breakthrough science with a first-in-class or best-in-class strategy across drug discovery, med tech, enabling technologies, and vaccines. The firm takes a hands-on, partnership-oriented approach with portfolio companies, providing intellectual capital and operational support to turn scientific innovation into approved medicines or medical products.
Differentiator
Problem solved
Functional benefit
Products and services
- Advent Life Sciences Venture Investment Services Trans-Atlantic venture capital investment and hands-on operational support for early and mid-stage life sciences companies pursuing first-in-class or best-in-class approaches across drug discovery, med tech, enabling technologies, and vaccines. Targeted at founders and management teams of innovative biotechnology and medical technology companies.
Quantifiable outcome
- 15 innovative medicines and products brought to approval since 2006
Companies that use Advent Life Sciences
Customer profileSegments1 record
Ideal customer profiles1 record
Advent Life Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Advent Life Sciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bioncotech Therapeuticsportfolio companyBioncotech Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, entered a Phase II clinical trial collaboration with MSD (Merck & Co.) for BO-112 combined with KEYTRUDA.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Advent Life Sciences competitors and assessment
Company assessmentDirect peers
- M Ventures: Venture arm of Merck KGaA investing across life sciences, including early-stage biotech and enabling technologies. Overlapping mandate with Advent's enabling-technologies and therapeutics scope.
- Index Ventures (Life Sciences): London/SF/New York venture firm with a dedicated life sciences practice investing in biotech across modalities from early to mid stages. Comparable transatlantic mandate and stage focus.
- EQT Life Sciences: European life sciences VC (formerly LSP) investing from seed to growth across biotech and medtech. Direct peer — has co-invested with Advent on Cyted Health Series B and shares the European-anchored transatlantic thesis.
- Sofinnova Partners: Paris- and London-headquartered VC firm exclusively dedicated to life sciences investing across early and mid-stage companies in drug discovery and medtech. Closest direct analogue to Advent's European-anchored transatlantic life sciences strategy.
- Forbion: Leading European life sciences VC investing in early to late-stage biotech and medtech. Comparable in transatlantic presence, therapeutic diversification and a track record of approvals/exits across portfolio companies.
- Abingworth: UK-based transatlantic life sciences and healthcare VC that invests across all clinical stages and modalities. Highly comparable firm by mandate and geographic focus.
- Novo Holdings (Novo Seeds / Novo Ventures): Copenhagen-headquartered life sciences investor running seed, venture and growth strategies. Comparable focus on first-in-class biotech and a long-dated, multi-stage European life sciences platform.
- AlbionVC: UK-based technology and life sciences VC investing at early stages across UK and Europe. Comparable in geography, size and stage focus though broader sector mandate than Advent.
- SV Health Investors: Boston/London-based specialist healthcare VC investing across biotech, medtech and growth-stage healthcare. Comparable therapeutic breadth and dual-continent approach to Advent.
Broad incumbents
- F-Prime Capital: Fidelity-affiliated global venture firm with a deep life sciences practice across biotech, medtech and healthcare. Larger incumbent that overlaps Advent's mandate at the upper end of stage range.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
Advent Life Sciences social profiles
Digital presenceAdvent Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Advent Life Sciences leadership team
Management profileNumber of profiles
Profiles4 records
Advent Life Sciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Advent Life Sciences M&A and investment
M&A and investmentM&A
Investments69 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Advent Life Sciences
What does Advent Life Sciences do?
Advent Life Sciences is a trans-Atlantic venture capital firm that founds and invests in early and mid-stage life sciences companies with first-in-class or best-in-class approaches to unmet medical needs. The firm provides venture capital, strategic guidance, and operational support across new drug discovery (all modalities), med tech, enabling technologies, and vaccines. It takes a hands-on, partnership-oriented approach working closely with portfolio management teams to advance breakthrough science toward approved medicines and medical products.
Is Advent Life Sciences a public or private company?
Advent Life Sciences is a private company. It is classified as management employee owned and is currently operating.
When was Advent Life Sciences founded?
Advent Life Sciences was founded in 2006. It employs 11 to 50 people.
Where is Advent Life Sciences based?
Advent Life Sciences is headquartered in London, United Kingdom, in the Europe region.
How does Advent Life Sciences make money?
One revenue line is on record: investment Returns.
Who are Advent Life Sciences's main competitors?
Direct peers on record are M Ventures, Index Ventures (Life Sciences), EQT Life Sciences, Sofinnova Partners, Forbion, Abingworth, Novo Holdings (Novo Seeds / Novo Ventures), AlbionVC and SV Health Investors. F-Prime Capital is listed as a broad incumbent.
Does Advent Life Sciences have an API?
No public API is recorded for Advent Life Sciences.
What industry is Advent Life Sciences in?
Advent Life Sciences's product category is Venture Capital (Life Sciences). Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 54169 and its SIC code is 6282.